Keyphrases
Acute Coronary Artery Disease
27%
Anemia
13%
Anticoagulant Therapy
13%
Anticoagulation
16%
Antithrombotic Therapy
13%
Assistance Model
13%
Association Score
13%
Atrial Fibrillation
100%
Cardiologists
13%
Cardiology
17%
Cardiovascular Disease
13%
Cardioversion
13%
Cost-effectiveness
13%
Dabigatran
20%
Diabetic Patients
13%
Direct Oral Anticoagulants
29%
Disease-associated
18%
Echocardiographic
13%
Elderly Patients
13%
Epidemiology
13%
European Heart Rhythm Association
13%
F12 Gene
13%
First Visit
13%
Function Maintenance
13%
Functional Class
13%
Heart Failure
16%
Homozygosity
13%
Iron Deficiency
13%
Ischemic Heart Disease
13%
Multiple Comorbidities
13%
New Evidence
13%
Non-valvular Atrial Fibrillation
33%
Patient Management
13%
Plasma Parameters
13%
Polymorphism
13%
Prescription Pattern
13%
Primary Care
13%
RE-LY
13%
Risk Factors
22%
Rivaroxaban
27%
Sinus Rhythm
13%
Spain
27%
Spanish Population
13%
Stroke Prevention
41%
Systemic Thromboembolism
13%
T Allele
13%
Thrombin-activatable Fibrinolysis Inhibitor
13%
Type 1 Diabetes Mellitus (T1DM)
13%
Vitamin K Antagonists
21%
Warfarin
22%
Medicine and Dentistry
Anemia
13%
Anticoagulation
13%
Antithrombotic
24%
Apoplexy
11%
Atrial Fibrillation
68%
Brain Ischemia
13%
Cardiac Dysrhythmia
9%
Cardiology
20%
Cardiovascular Disease
13%
Clinical Trial
6%
Cohort Effect
13%
Comorbidity
15%
Congestive Heart Failure
13%
Diabetes
5%
Diabetes Mellitus
13%
Direct Oral Anticoagulant
27%
Elderly Patient
13%
Iron Deficiency
13%
Ischemic Heart Disease
13%
Primary Health Care
13%
Revascularization
5%
Rivaroxaban
13%
Thromboembolism
21%
Vitamin K Antagonist
17%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
22%
Anticoagulation Therapy
6%
Antivitamin K
21%
Atrial Fibrillation
82%
Bleeding
10%
Cardiovascular Disease
13%
Cerebrovascular Accident
50%
Clinical Trial
12%
Comorbidity
13%
Coronary Artery Disease
13%
Dabigatran
20%
Diabetes Mellitus
13%
Direct Oral Anticoagulant
18%
Rivaroxaban
27%
Thrombin Activatable Fibrinolysis Inhibitor
13%
Thromboembolism
32%
Warfarin
22%